• Markets
    • icon
  • Companies
RAC · ASX

Race Oncology Ltd. (ASX:RAC)

AU$1.6

 -0.055 (-3.313%)
ASX:Live
26/07/2024 04:10:15 PM
Hammer Bullish HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RAC Overview

RAC Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Strong

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About RAC

Website

Race Oncology Ltd.

Telephone

61.2.8051.3043

Address

Level 36, Gateway 1 Macquarie Place Sydney, New South Wales (NSW) 2000

Description

Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The firm is involved in developing Bisantrene, a small molecule anthracene chemotherapeutic, to address the unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer and acute myeloid leukemia. It is also investigating the impact Bisantrene and new molecules have on the m6A RNA pathway. The company was founded on February 15, 2011 and is headquartered in Sydney, Australia.

RAC Price Chart

Key Stats

Market Cap

AU$278.53M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.64 - 2.09

Trade Value (12mth)

AU$52,024.00

1 week

-9.29%

1 month

-8.54%

YTD

95.29%

1 year

25.76%

All time high

4.23

Key Fundamentals

EPS 3 yr Growth

70.900%

EBITDA Margin

N/A

Operating Cashflow

-$11m

Free Cash Flow Return

-34.60%

ROIC

-32.20%

Interest Coverage

N/A

Quick Ratio

20.40

Other Data

Shares on Issue (Fully Dilluted)

163m

HALO Sector

Healthcare

Next Company Report Date

23-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

RAC Announcements

Latest Announcements

Date Announcements

25 July 24

Race to Present at TechKnow July Conference

×

Race to Present at TechKnow July Conference

25 July 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

23 July 24

Quarterly Activity Report and Appendix 4C

×

Quarterly Activity Report and Appendix 4C

18 July 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

12 July 24

Bioshares 18th Biotech Summit Presentation

×

Bioshares 18th Biotech Summit Presentation

11 July 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

04 July 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

02 July 24

Distinguished Oncologist Daniel Von Hoff Joins as Consultant

×

Distinguished Oncologist Daniel Von Hoff Joins as Consultant

01 July 24

Race In-person Investor Briefing Invitation Perth

×

Race In-person Investor Briefing Invitation Perth

27 June 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

26 June 24

RC220 GLP Non-clinical Toxicology Program Successful

×

RC220 GLP Non-clinical Toxicology Program Successful

20 June 24

Race Appoints George Clinical for Phase 1 Trial of RC220

×

Race Appoints George Clinical for Phase 1 Trial of RC220

20 June 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

18 June 24

FDA RPD Designation Granted for RC220 Bisantrene

×

FDA RPD Designation Granted for RC220 Bisantrene

13 June 24

Bisantrene Highly Active in a Multiple Myeloma Mouse Model

×

Bisantrene Highly Active in a Multiple Myeloma Mouse Model

13 June 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

11 June 24

Notification of cessation of securities - RAC

×

Notification of cessation of securities - RAC

11 June 24

US FDA Orphan Drug Designation Awarded to RC220 Bisantrene

×

US FDA Orphan Drug Designation Awarded to RC220 Bisantrene

06 June 24

Bonus Options Offer Results

×

Bonus Options Offer Results

06 June 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

06 June 24

Notification regarding unquoted securities - RAC

×

Notification regarding unquoted securities - RAC

30 May 24

Appendix 3Y-Phillip Lynch

×

Appendix 3Y-Phillip Lynch

30 May 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

30 May 24

Notification regarding unquoted securities - RAC

×

Notification regarding unquoted securities - RAC

30 May 24

Appendix 3Y-Mary Harney

×

Appendix 3Y-Mary Harney

RAC Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.05 -0.07 -0.06 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.05 -0.07 -0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock -34.1 -51.0 15.6 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A 22.0 N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A 24.3 N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.05 -0.06 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.04 -0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock -24.6 -85.5 -12.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -1.0 -2.1 -5.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A 0.0 N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.10 0.23 0.16 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.07 0.21 0.14 Lock Lock Lock
     Growth % Lock Lock Lock Lock 365.5 192.8 -33.1 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 131 153 161 Lock Lock Lock
Basic m Lock Lock Lock Lock 131 153 161 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 6 11 13 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -6 -11 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -68.4 -80.9 -13.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -6 -11 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -63.5 -77.4 -13.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -7 -12 -13 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -1 -3 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -6 -11 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -64.9 -76.7 11.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -5 -6 -11 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 12 31 -1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -5 -6 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -90.7 -33.2 -70.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 9 34 22 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 14 38 27 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -9 -34 -22 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 14 36 25 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 14 36 25 Lock Lock Lock
     Growth % Lock Lock Lock Lock 141.2 163.1 -29.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -44.5 -29.9 -37.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -46.2 -31.0 -38.9 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -66.7 -46.1 -42.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -65.3 -45.0 -32.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -48.4 -25.1 -34.6 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.5 3.0 1.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -67.9 -92.9 -84.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 20.2 24.1 20.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 20.2 24.1 20.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 88.0 98.2 91.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -898.0 -441.5 -924.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -44.5 -29.9 -37.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.0 1.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -46.2 -31.0 -38.9 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -46.2 -31.0 -38.9 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 288.4 743.5 955.5 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -288.4 -743.5 -955.5 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RAC Shortsell

Frequently Asked Questions

The current share price of Race Oncology Ltd. (RAC:ASX) is AU$1.6.
The 52-week high share price for Race Oncology Ltd. (RAC:ASX) is AU$2.09.
The 52-week low share price for Race Oncology Ltd. (RAC:ASX)? is AU$0.64.
Race Oncology Ltd. (RAC:ASX) does not pay a dividend.
Race Oncology Ltd. (RAC:ASX) does not pay a dividend.
Race Oncology Ltd. (RAC:ASX) has a franking level of 0.0%.
Race Oncology Ltd. (RAC:ASX) is classified in the Healthcare.
The current P/E ratio for Race Oncology Ltd. (RAC:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.